Pembrolizumab in Combination with Radiotherapy for Metastatic Melanoma - Introducing the PERM Trial.

Thumbnail Image

Files

Clinical Oncology Submission PERM trial (Manuscript for submission 19_11_2017).pdf (216.7 KB)

Embargo End Date

ICR Authors

Harrington, Kevin
 Melcher, Alan
 Larkin, James

Authors

Yip, K
Melcher, A
Harrington, K
Illidge, T
Nobes, J
Webster, A
Smith, D
Lorigan, P
Nathan, P
Larkin, J

Document Type

Journal Article

Date

2018-04

Date Accepted

2017-12-14

Abstract

Citation

Clinical oncology (Royal College of Radiologists (Great Britain)), 2018, 30 (4), pp. 201 - 203

DOI

10.1016/j.clon.2018.01.001

URI

https://repository.icr.ac.uk/handle/internal/1657

Rights

https://www.rioxx.net/licenses/under-embargo-all-rights-reserved

Source Title

Publisher

ISSN

0936-6555

eISSN

1433-2981

Collections

Cell and Molecular Biology
Clinical Studies
Radiotherapy and Imaging

Research Team

Melanoma and Kidney Cancer
Targeted Therapy
Translational Immunotherapy

Notes